Filtered By:
Specialty: Drugs & Pharmacology
This page shows you your search results in order of date.
Order by Relevance | Date
Total 123144 results found since Jan 2013.
Oxytocin treatment for core symptoms in children with autism spectrum disorder: a systematic review and meta-analysis
ConclusionWhile the therapeutic value of oxytocin in treating core symptoms of ASD in children is not fully established, the results of this meta-analysis indicate a potential moderate effect. However, further studies with larger sample sizes and more robust RCTs are needed to directly demonstrate the efficacy of oxytocin. Future research should also focus on effect size and outcome evaluation accuracy while minimizing bias in RCT experiments.
Source: European Journal of Clinical Pharmacology - September 22, 2023 Category: Drugs & Pharmacology Source Type: research
LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data
ConclusionsThis study showed that not all LABA/LAMA FDCs were superior to LABA/ICS FDCs in safety and in preventing moderate or severe exacerbations in patients with stable COPD, providing important quantitative information for COPD-related guidelines.
Source: European Journal of Clinical Pharmacology - September 22, 2023 Category: Drugs & Pharmacology Source Type: research
Dipeptidyl-peptidase-4 inhibitors have anti-inflammatory effects in patients with type 2 diabetes
ConclusionThis meta-analysis demonstrated that DPP-4 inhibitors can significantly attenuate low-grade inflammatory state in patients with T2DM. In addition to improving glycemic control, DDP-4 inhibitors might offer extra therapeutic value by controlling inflammation.Graphical Abstract
Source: European Journal of Clinical Pharmacology - September 22, 2023 Category: Drugs & Pharmacology Source Type: research
Impact of tofogliflozin on hepatic outcomes: a systematic review
ConclusionOverall, an improvement in levels of hepatic parameters was observed in T2DM patients with concurrent liver disorders. However, a large number of clinical trials are needed to prove the efficacy of tofogliflozin on hepatic outcomes in patients with T2DM.
Source: European Journal of Clinical Pharmacology - September 22, 2023 Category: Drugs & Pharmacology Source Type: research
Is Pain a Symptom or a Disease? How Does the New Evidence Help to Better Understand this Unsolved Question?
Curr Neuropharmacol. 2023 Sep 21. doi: 10.2174/1570159X2201230921165106. Online ahead of print.NO ABSTRACTPMID:37735864 | DOI:10.2174/1570159X2201230921165106
Source: Current Neuropharmacology - September 22, 2023 Category: Drugs & Pharmacology Authors: Massimo Allegri Source Type: research
Artificial Intelligence for Drug Discovery: Are We There Yet?
Annu Rev Pharmacol Toxicol. 2023 Sep 22. doi: 10.1146/annurev-pharmtox-040323-040828. Online ahead of print.ABSTRACTDrug discovery is adapting to novel technologies such as data science, informatics, and artificial intelligence (AI) to accelerate effective treatment development while reducing costs and animal experiments. AI is transforming drug discovery, as indicated by increasing interest from investors, industrial and academic scientists, and legislators. Successful drug discovery requires optimizing properties related to pharmacodynamics, pharmacokinetics, and clinical outcomes. This review discusses the use of AI in ...
Source: Pharmacological Reviews - September 22, 2023 Category: Drugs & Pharmacology Authors: Catrin Hasselgren Tudor I Oprea Source Type: research
Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine
Annu Rev Pharmacol Toxicol. 2023 Sep 22. doi: 10.1146/annurev-pharmtox-022723-113921. Online ahead of print.ABSTRACTProteogenomics refers to the integration of comprehensive genomic, transcriptomic, and proteomic measurements from the same samples with the goal of fully understanding the regulatory processes converting genotypes to phenotypes, often with an emphasis on gaining a deeper understanding of disease processes. Although specific genetic mutations have long been known to drive the development of multiple cancers, gene mutations alone do not always predict prognosis or response to targeted therapy. The benefit of p...
Source: Pharmacological Reviews - September 22, 2023 Category: Drugs & Pharmacology Authors: Sunil K Joshi Paul Piehowski Tao Liu Sara J C Gosline Jason E McDermott Brian J Druker Elie Traer Jeffrey W Tyner Anupriya Agarwal Cristina E Tognon Karin D Rodland Source Type: research
The ASHP House of Delegates: Reflecting on 75 years of advancing health
Am J Health Syst Pharm. 2023 Sep 21:zxad227. doi: 10.1093/ajhp/zxad227. Online ahead of print.ABSTRACTIn an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.PMID:37738619 | DOI:10.1093/ajhp/zxad227
Source: American Journal of Health-System Pharmacy : AJHP - September 22, 2023 Category: Drugs & Pharmacology Authors: Daniel J Cobaugh Source Type: research
A Survey of the Status of Methadone Switching in Japan Using a Hospital-Based Administrative Claims Database
In conclusion, more than 30% of the patients underwent high-dose methadone switching and required long completion periods, suggesting that methadone switching remains challenging in Japan. This article is protected by copyright. All rights reserved.PMID:37737471 | DOI:10.1002/jcph.2351
Source: The Journal of Clinical Pharmacology - September 22, 2023 Category: Drugs & Pharmacology Authors: Shungo Imai Natsumi Aoki Keisuke Ikegami Hayato Kizaki Satoko Hori Source Type: research
Artificial Intelligence for Drug Discovery: Are We There Yet?
Annu Rev Pharmacol Toxicol. 2023 Sep 22. doi: 10.1146/annurev-pharmtox-040323-040828. Online ahead of print.ABSTRACTDrug discovery is adapting to novel technologies such as data science, informatics, and artificial intelligence (AI) to accelerate effective treatment development while reducing costs and animal experiments. AI is transforming drug discovery, as indicated by increasing interest from investors, industrial and academic scientists, and legislators. Successful drug discovery requires optimizing properties related to pharmacodynamics, pharmacokinetics, and clinical outcomes. This review discusses the use of AI in ...
Source: Annual Review of Pharmacology and Toxicology - September 22, 2023 Category: Drugs & Pharmacology Authors: Catrin Hasselgren Tudor I Oprea Source Type: research
Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine
Annu Rev Pharmacol Toxicol. 2023 Sep 22. doi: 10.1146/annurev-pharmtox-022723-113921. Online ahead of print.ABSTRACTProteogenomics refers to the integration of comprehensive genomic, transcriptomic, and proteomic measurements from the same samples with the goal of fully understanding the regulatory processes converting genotypes to phenotypes, often with an emphasis on gaining a deeper understanding of disease processes. Although specific genetic mutations have long been known to drive the development of multiple cancers, gene mutations alone do not always predict prognosis or response to targeted therapy. The benefit of p...
Source: Annual Review of Pharmacology and Toxicology - September 22, 2023 Category: Drugs & Pharmacology Authors: Sunil K Joshi Paul Piehowski Tao Liu Sara J C Gosline Jason E McDermott Brian J Druker Elie Traer Jeffrey W Tyner Anupriya Agarwal Cristina E Tognon Karin D Rodland Source Type: research
Alpha-lipoic acid, apocynin or probiotics influence glutathione status and selected inflammatory parameters in C57/BL6 mice when combined with a low-fat diet
CONCLUSIONS: Supplementation of the tested compounds with LFD appears to have a positive influence on the glutathione redox status of pulmonary tissues and selected inflammatory parameters in mouse blood.PMID:37730940 | DOI:10.1007/s43440-023-00527-8
Source: Pharmacological Reports - September 21, 2023 Category: Drugs & Pharmacology Authors: Paulina Kleniewska Rafa ł Pawliczak Source Type: research
Par3L, a polarity protein, promotes M1 macrophage polarization and aggravates atherosclerosis in mice via p65 and ERK activation
In this study, we investigated the roles of the polar protein Par3L in M1 macrophage polarization and atherosclerosis. To induce atherosclerosis, Apoe-/- mice were fed with an atherosclerotic Western diet for 8 or 16 weeks. We showed that Par3L expression was significantly increased in human and mouse atherosclerotic plaques. In primary mouse macrophages, oxidized low-density lipoprotein (oxLDL, 50 μg/mL) time-dependently increased Par3L expression. In Apoe-/- mice, adenovirus-mediated Par3L overexpression aggravated atherosclerotic plaque formation accompanied by increased M1 macrophages in atherosclerotic plaques and bo...
Source: Acta Pharmacologica Sinica - September 21, 2023 Category: Drugs & Pharmacology Authors: Yi-Min Huang Yu-Sen Wu Yuan-Ye Dang Yi-Ming Xu Kong-Yang Ma Xiao-Yan Dai Source Type: research
Physiologically Based Pharmacokinetic Modeling of the Drug-Drug Interaction Between CYP3A4 Substrate Glasdegib and Moderate CYP3A4 Inducers in Lieu of a Clinical Study
This article is protected by copyright. All rights reserved.PMID:37731282 | DOI:10.1002/jcph.2348
Source: The Journal of Clinical Pharmacology - September 21, 2023 Category: Drugs & Pharmacology Authors: Ernesto Callegari Susanna Tse Angela C Doran Theunis C Goosen Naveed Shaik Source Type: research
Temporal evolution of antiretroviral therapy (2017-2021): analysis of treatment change and its economic impact
CONCLUSIONS: Optimization/simplification accounts for almost half of the reasons for TAR change, with an economic impact that, despite the inflection point of 2019, each year manages to exceed the previous one, achieving a progressive cost reduction maintained over time.PMID:37731312 | DOI:10.37201/req/047.2023
Source: Revista Espanola de Quimioterapia - September 21, 2023 Category: Drugs & Pharmacology Authors: E Herranz-Bayo H Navarro-Azn árez A Pinilla-Rello C I D íaz-Calderón-Horcada Source Type: research
